Are you a CIPA member?
Sign in to your account to register for the event
If you are not yet registered or a member of CIPA, please register here
- News
- News
- NewsMedia
- Events
- Events
- EventsIntroductory Patent Paralegal CourseAdvanced Patent Paralegal Course (APPC)
- Advice
- Advice
- IP explainedResources
- Members
- Members
- MembershipBrand & Marketing Materials
- Publications
- Publications
- Online ShopCIPA JournalDownloads
- Jobs
- About Us
×Event Listing
An overview of SPCs in Europe – What does the future hold?
5Jun
Webinar An overview of SPCs in Europe – What does the future hold?
Thursday 5 June
Location
Join us on Thursday 5 June 2025 for a webinar on Supplementary Protection Certificates (SPCs) in Europe, presented by Ben Heller and Beth Ormrod. We will provide an overview of the regulatory framework and the requirements for obtaining a SPC in Europe, upcoming developments in view of the UPC and current EU Commission proposals as well as how Brexit and the Windsor Framework have affected the landscape in the UK and Europe.
Audience
Paralegals
Speakers
Beth Ormrod, Kilburn & StrodeBeth Ormrod, Kilburn & Strode
Beth’s practice spans a variety of fields in the life sciences. Key areas of practice include stem cells, antibodies, tissue engineering, CRISPR-Cas9 and RNA technologies. She also has valuable in-house experience gained during a secondment at a multinational pharmaceutical company. She co-ordinates worldwide patent prosecution of large portfolios and complex IP strategies for large multinationals. She also works closely with her start-up clients to formulate IP strategies that support the client’s business and commercial needs, as well as preparing and filing foundational patent applications and assisting with freedom-to-operate analysis. Beth has experience of working with clients throughout all stages of clinical trial candidate development, including supporting them to obtain valuable patent and SPC protection.
Ben Heller, Kilburn & StrodeBen Heller, Kilburn & Strode
Ben handles patent applications spanning a broad range of chemical technologies. He specialises in particular in pharmaceutical chemistry, including new chemical entities, drug delivery formulations, nanomaterials, medical uses, dosing regimens and combination therapies. Ben represents clients at all stages of the development process, from small-molecule target identification to clinical trial drug candidates and marketed drug products. He and his team are responsible for high-value European portfolios for a number of clients covering EMA and US FDA-approved drug products, advising clients on the strategic use of IP to deliver on their commercial objectives. Alongside the drafting and prosecution of patent applications, Ben’s has an excellent track record in defending his clients’ patents in EPO opposition and appeal proceedings covering a number of commercially important drugs. He also has particular expertise in obtaining SPC across Europe for approved drug products and regularly presents on this topic in the UK and US.
Shopping Bag (0)